Pulse Biosciences Inc
NASDAQ:PLSE
Intrinsic Value
Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of PLSE.
Fundamental Analysis
Finance and Clinical Updates from Earnings Call
2023-Q3 Earnings Call
In a recent quarterly call, the company revealed a substantial reduction in non-GAAP total costs and expenses, lowering them from $16.8 million in the previous year to $9.2 million. This was attributed to headcount decreases and a significant inventory reserve in the prior year. R&D costs climbed by $2.3 million to support the advancement of Cardiology devices. The non-GAAP net loss was halved from $16.8 million to $8.5 million year-over-year, and they ended the quarter with $50.4 million in cash. Going forward, cash use is expected to be around $8 million in Q4 2023. The company also discussed their CellFX nsPFA technology's potential in treating atrial fibrillation and benign thyroid nodules, where it appears to be a superior alternative to existing therapies, hinting at significant market opportunities in both areas.
Balance Sheet Decomposition
Pulse Biosciences Inc
Current Assets | 51.6m |
Cash & Short-Term Investments | 50.4m |
Other Current Assets | 1.2m |
Non-Current Assets | 14.3m |
PP&E | 9.1m |
Intangibles | 4.8m |
Other Non-Current Assets | 380k |
Current Liabilities | 5.4m |
Accounts Payable | 1.4m |
Accrued Liabilities | 4m |
Non-Current Liabilities | 8.4m |
Other Non-Current Liabilities | 8.4m |
Earnings Waterfall
Pulse Biosciences Inc
Revenue
|
-10k
USD
|
Cost of Revenue
|
-1.3m
USD
|
Gross Profit
|
-1.3m
USD
|
Operating Expenses
|
-38.5m
USD
|
Operating Income
|
-39.8m
USD
|
Other Expenses
|
310k
USD
|
Net Income
|
-39.5m
USD
|
Free Cash Flow Analysis
Pulse Biosciences Inc
What is Free Cash Flow?
PLSE Profitability Score
Profitability Due Diligence
Pulse Biosciences Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
Score
Pulse Biosciences Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
PLSE Solvency Score
Solvency Due Diligence
Pulse Biosciences Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Score
Pulse Biosciences Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PLSE Price Targets Summary
Pulse Biosciences Inc
According to Wall Street analysts, the average 1-year price target for PLSE is 5 USD .
Ownership
PLSE Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
PLSE Price
Pulse Biosciences Inc
Average Annual Return | -17.68% |
Standard Deviation of Annual Returns | 62.58% |
Max Drawdown | -97% |
Market Capitalization | 479m USD |
Shares Outstanding | 54 923 000 |
Percentage of Shares Shorted | 14.83% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. The company is headquartered in Hayward, California and currently employs 142 full-time employees. The company went IPO on 2016-05-18. The firm provides CellFX System, which is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. The CellFX System includes a multi-use handpiece and a suite of single-patient use treatment tips ranging from approximately 1.5 square millimeter (mm2) to 10 mm2, enabling treatment of a variety of lesion sizes and depths. The treatment tips wirelessly connect to the CellFX System when plugged into the handpiece, allowing for the use of automated treatment settings based on the treatment tip used. The firm has commercialized its CellFX System into the procedure market as its commercial market. Powered by the Company’s Nano-Pulse Stimulation (NPS) technology, the CellFX System delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue.